H.C. Wainwright upgraded Oncternal Therapeutics to Buy from Neutral with a $2 price target. Considering the efficacy results for zilovertamab vedotin as well as the preclinical results for ONCT-808, the firm is now including risk-adjusted sales for ONCT-808 in 3L diffuse large B cell lymphoma. While cancer cell growth rebounded in mice treated with the lowest dose, both the intermediate and the high doses of anti-ROR1 CAR-T cells were able to stabilize the cancer cell burden at a low level, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ONCT:
- Oncternal Therapeutics announces Prostate Cancer Scientific Advisory Board
- Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
- Oncternal Therapeutics reports Q2 EPS ,(15c) consensus (16c)
- Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
- Oncternal Therapeutics (ONCT) Q2 Earnings Cheat Sheet